Biogen Takes Aim At Amgen’s Tavneos With Vanqua Licensing Pact

 
• By Joseph Haas
  
Biogen licenses preclinical asset from Vanqua that may compete with Amgen's Tavneos (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business